🧪 CJC-1295 DAC — Research Peptide

Chemical Name: CJC-1295 with Drug Affinity Complex (DAC)
CAS Number: 863288-34-0
Synonyms: Modified GRF (1-29), CJC-1295-DAC, tetrasubstituted GHRH analogue, DAC-GRF(1-29)
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: ≈ 3367.9 Da

🔬 Overview

CJC-1295 DAC is a synthetic analogue of growth hormone–releasing hormone (GHRH) designed for extended half-life and stability in research applications.
The DAC (Drug Affinity Complex) addition allows for prolonged peptide circulation, facilitating sustained GHRH receptor activation in preclinical studies.

Regulatory Status:
CJC-1295 DAC is not approved by the U.S. Food and Drug Administration (FDA) for human use.
It is supplied strictly for laboratory, in vitro, or preclinical animal research and not for human or veterinary consumption.

⚗️ Chemical & Physical Properties

Property	Specification
CAS No.	863288-34-0
Sequence	Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-NH₂ (modified with Drug Affinity Complex)
Molecular Formula	C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight	3367.9 g/mol
Appearance	White lyophilized powder
Solubility	Soluble in sterile water or bacteriostatic saline
Storage	Store below –20 °C; protect from light and moisture

📘 Research Context (Preclinical Literature)

The studies cited below are for scientific context only and not to imply any therapeutic or diagnostic use.

Teichman SL, et al. CJC-1295, a long-acting GHRH analogue, increases GH and IGF-I levels in healthy adults.
J Clin Endocrinol Metab. 2006;91(2):799-805.
PubMed: 16263830
Fahy JL, et al. Pharmacokinetics and safety of a sustained-release GHRH analogue (CJC-1295).
Clin Pharmacol Ther. 2005;78(2):221-229.
PubMed: 16084850
Al-Shanti N, Stewart CE. Mechanistic insight into GH regulation using GHRH analogues.
Growth Horm IGF Res. 2009;19(3):239-245.
PubMed: 19171430

⚠️ Regulatory & Compliance Statement

For Research Use Only.
Not for Human or Veterinary Use.
Not FDA-approved for therapeutic, cosmetic, or dietary applications.
No claims are made for diagnosis, treatment, or prevention of disease.
Labeling Example:

Product: CJC-1295 DAC
CAS: 863288-34-0
Purity: ≥98% (HPLC)
Form: Lyophilized powder
Intended Use: Laboratory and in vitro research only. Not for injection or human consumption.
Storage: –20 °C, dry and dark conditions.

🔍 SEO & Keyword Optimization (Compliant Terms)

Primary Keywords:
CJC-1295 DAC research peptide, CJC-1295 CAS 863288-34-0, Modified GRF 1-29 DAC, CJC-1295 peptide for laboratory use, GHRH analogue research, long-acting GHRH peptide, CJC-1295 DAC molecular data

Secondary Keywords:
CJC-1295 peptide study, growth hormone releasing hormone analogue, DAC peptide research, laboratory peptide supplier, scientific peptide CAS 863288-34-0

📚 Suggested Reference Links (for “Further Reading”)

Teichman SL, et al. CJC-1295, a long-acting GHRH analogue, increases GH and IGF-I in healthy adults.
J Clin Endocrinol Metab. 2006;91(2):799-805.
PubMed: 16263830
Rahim A, et al. Sustained GHRH analogue administration and GH axis modulation.
J Clin Endocrinol Metab. 1998;83(10):3561-3567.
PubMed: 9768653
Fahy JL, et al. Safety and pharmacokinetics of CJC-1295 in human studies.
Clin Pharmacol Ther. 2005;78(2):221-229.
PubMed: 16084850

✅ Summary (For Research Catalog Use)

CJC-1295 DAC (CAS 863288-34-0) is a long-acting synthetic analogue of growth hormone–releasing hormone used in biochemical and endocrine research to study extended-duration peptide receptor activity.
Supplied as a high-purity research peptide, this compound is intended solely for scientific investigation and not approved for human use.